PerioTrap develops an innovative anti-infective drug for the curative treatment of periodontitis, an inflammatory gum disease caused by specific bacteria. Although this is a common indication associated with a range of comorbidities currently concerning around 30% of the global population, there is no effective treatment on the market yet. Moreover, the most relevant therapy option to date is a painful procedure consisting of the manual removal of plaque within the dental pockets followed by cleansing using either antiseptic solutions or broad spectrum antibiotics. This however leads to various side effects. Besides the potential development of antimicrobial resistances, the current treatment also results in the destruction of the protective biofilm which usually functions as a natural protective layer.
Therefore, PerioTrap develops locally applied small molecule drugs that address a new target, which is only present within the pathogenic bacteria, but will not affect commensals. Thus, pathogens within the biological flora of the dental pocket will be selectively removed without affecting the protective biofilm. Furthermore, a local long-term release of our formulation will maintain its physiological function by preventing a pathogenic recolonization of the dental pockets which typically causes the reoccurrence of periodontitis. Accordingly, PerioTrap aims to eradicate the root of the disease and to ultimately restore patient confidence.
Therefore, PerioTrap develops locally applied small molecule drugs that address a new target, which is only present within the pathogenic bacteria, but will not affect commensals. Thus, pathogens within the biological flora of the dental pocket will be selectively removed without affecting the protective biofilm. Furthermore, a local long-term release of our formulation will maintain its physiological function by preventing a pathogenic recolonization of the dental pockets which typically causes the reoccurrence of periodontitis. Accordingly, PerioTrap aims to eradicate the root of the disease and to ultimately restore patient confidence.
Location: Germany, Saxony-Anhalt, Halle (Saale)
Employees: 11-50
Total raised: $3.56M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 22.10.2020 | bmp Ventur... | bmp.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.10.2020 | Seed | $3.56M | - |
Mentions in press and media 3
| Date | Title | Description |
| 12.03.2026 | European Startups Ignite Innovation with Fresh Capital and Strategic Acquisitions | European tech registered substantial activity. Berlin FinTech finperks secured $4 million for its prepaid market API infrastructure. This capital fuels engineering expansion and European market growth. US company Superhuman acquired AI data... |
| 11.03.2026 | finperks erhält 4 Millionen – PerioTrap bekommt 2,9 Millionen – Superhuman übernimmt Rows | Im #DealMonitor für den 11. März werfen wir einen Blick auf die wichtigsten, spannendsten und interessantesten Investments und Exits des Tages in der DACH-Region. Alle Deals der Vortage gibt es im großen und übersichtlichen #DealMonitor-Arc... |
| 21.10.2020 | PerioTrap Pharmaceuticals raises €3M seed round to develop selective anti-infectives to tackle periodontitis | Halle (Saale), 21.10.2020 – Although periodontitis is a widespread infectious disease affecting around 30% of the global population, there are currently no effective treatments available — yet. PerioTrap Pharmaceuticals, a Fraunhofer IZI ... |